In a rapidly evolving world with progressing technology, the biotechnology sector has gained significant attention from both investors and the general public. Over the past few years, biotech companies have been at the forefront of scientific breakthroughs that aim to improve human health and welfare. As a result, many investors are now searching for the best-performing biotech stocks to add to their portfolios.
In this article, we explore the top five biotech stocks that have outperformed in recent years and present solid growth potential in 2021.

1. Moderna Inc. (NASDAQ: MRNA)

A household name amid the COVID-19 pandemic, Moderna has been one of the leading companies in developing and producing a successful coronavirus vaccine. The company continues to gain revenue from its flagship product, mRNA-1273, and is actively involved in further vaccine research. Additionally, Moderna is expanding its capacity to manufacture and distribute its vaccines globally.

2. Novavax Inc. (NASDAQ: NVAX)

Another biotech company heavily involved in COVID-19 vaccine development is Novavax. They have successfully advanced their candidate NVX-CoV2373 into Phase 3 clinical trials with promising results so far, including efficacy against emerging strains of the virus. Investors can expect continued growth as agreements and purchase orders for Novavax’s vaccine are increasing worldwide.

3. Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Regeneron Pharmaceuticals is known for its robust drug pipeline targeting a wide range of therapeutic areas like oncology, eye diseases, infectious diseases, and allergies. Its monoclonal antibody cocktail REGEN-COV2 has been authorized for emergency use as a COVID-19 treatment in various countries. The company has consistently reported increased revenue over the past years, making it an attractive addition to a diversified portfolio.

4. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

Vertex Pharmaceuticals focuses on developing transformative medicines for people with serious genetic diseases. Its flagship medicine, Trikafta, is a treatment for cystic fibrosis that has shown remarkable efficacy and sales growth. Vertex’s strong financials, coupled with an impressive pipeline of innovative therapies, make it one of the best-performing biotech stocks in the market.

5. Crispr Therapeutics AG (NASDAQ: CRSP)

CRISPR technology has emerged as a revolutionary tool in genome editing, and Crispr Therapeutics is at the forefront of this field. They have multiple ongoing clinical trials to develop therapies for hemoglobinopathies, immunotherapies for cancer and regenerative medicine treatments using gene-edited cell lines. As more breakthroughs are achieved through their research, Crispr Therapeutics promises strong growth potential in the coming years.

In conclusion, these five biotech stocks have demonstrated impressive performance and innovation in recent years. As a prudent investor, it is crucial to further research these companies and consider potential risks before making any investment decisions. However, there is no denying that biotechnology holds incredible promise, and these companies may very well shape the future of medicine.